UK-based Cellular Origins — a spin-out from TTP Group — announced the completion of a $40 million (EUR 34.3 million) over-subscribed Series A round.
The financing was led by Johnson & Johnson, through its corporate venture capital organization JJDC, with participation from Highland Europe, BGF, NYBC Ventures, and TTP Group.
Cellular Origins aims to remove the barrier to scale by applying its proprietary robotic automation to connect individual third party unit operations already used in cell therapy processes. The resulting Constellation platform preserves biological performance and delivers a low-risk and space-efficient pathway to scale that pharma companies need.
Cellular Origins will use the financing to expand its commercial team as well as broaden the range of unit operations integrated into the company’s platform. The investment also enables the company to build the systems and infrastructure needed for full manufacturing and services scale-up. Looking ahead, Cellular Origins will extend its capabilities beyond cell therapies into the wider ATMP sector.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!